Corporate Updates

GE Healthcare gets License for New Imaging Agent

GE Healthcare acquired the license to a new molecular imaging agent that could be useful in diagnosing heart attacks and monitoring how well tumors respond to drugs.

Developed by Ming Zhao, Ph.D., an assistant professor in biophysics at the Medical College of Wisconsin in Milwaukee, Wis., the tracer binds to dying cells, making it useful for doctors who want to detect damage to the heart, figure out if a tumour is weakening in response to treatment, or find hidden internal injuries. So if tagged with a gamma-based radioactive tracer, such as an isotope of technetium, or even a fluorolabel, the molecule could becoming visible to the appropriate nuclear medicine modality, such as PET or SPECT.


Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top